Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (38)
  • Open Access


    Nimotuzumab Combined with Neoadjuvant or Induction Chemotherapy for Head and Neck Squamous Cell Carcinoma: A Retrospective Study

    Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou*

    Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023

    Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and… More >

  • Open Access


    PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells


    Oncology Research, Vol.29, No.4, pp. 235-250, 2021, DOI:10.32604/or.2022.025323

    Abstract Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells… More >

  • Open Access


    Progression of Exosome-Mediated Chemotherapy Resistance in Cancer

    Haojie Zhang1, Xiaohong Wang2,*, Yue Yu2, Zhenlin Yang3,*

    Oncologie, Vol.24, No.2, pp. 247-259, 2022, DOI:10.32604/oncologie.2022.020993

    Abstract Chemotherapy plays an important role in controlling cancer progression, but the long-term use of chemotherapeutic agents can lead to drug resistance and eventually treatment failure. Therefore, elucidation of the mechanism of drug resistance is the key to solve the problem of chemotherapy resistance. In recent years, exosomes derived from tumor cells have received extensive attention from researchers. In this paper, we reviewed the role and mechanism of exosome-mediated tumor drug resistance in recent years, summarized the related studies of exosome and chemotherapy drug resistance, and focused on several different ways by which exosomes participate in More >

  • Open Access


    Adjuvant Chemotherapy Following Surgical Resection Improves Survival in Patients With Early Stage Small Cell Lung Cancer

    Yuanshan Yao, Yinjie Zhou, Zhenhua Yang, Hongbo Huang, Haibo Shen

    Oncology Research, Vol.27, No.2, pp. 203-210, 2019, DOI:10.3727/096504018X15202953107093

    Abstract The purpose of this study was to determine the effects of resection coupled with standard chemotherapy on the survival prognosis of patients with early stage small cell lung carcinoma (SCLC). Patients (n=110) with mediastinal lymph node-negative SCLC were enrolled in this study. The baseline clinical data of patients with surgery were retrospectively reviewed. Overall survival (OS) and progression-free survival (PFS) were measured by Kaplan–Meier and log-rank test analyses. Ninety-eight patients received mediastinoscopy biopsy, and pulmonary lobectomy or sublobar resection, and 67 patients underwent adjuvant chemotherapy after pulmonary lobectomy. Adjuvant chemotherapy after surgical intervention was associated… More >

  • Open Access


    Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study

    Jing Tang*1, Xu Yong Li†1, Jing Bo Liang, De Wu§, Li Peng, Xiaobing Li

    Oncology Research, Vol.27, No.6, pp. 635-641, 2019, DOI:10.3727/096504018X15288447760357

    Abstract Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a… More >

  • Open Access


    Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy

    Takashi Saito*†, Atsuo Okamura, Junichiro Inoue, Daisuke Makiura, Hisayo Doi§, Kimikazu Yakushijin, Hiroshi Matsuoka, Yoshitada Sakai†#, Rei Ono*

    Oncology Research, Vol.27, No.4, pp. 469-474, 2019, DOI:10.3727/096504018X15267574931782

    Abstract Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n=9; diffuse large B-cell lymphoma; n=31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range=27–76 years). Statistical More >

  • Open Access


    Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

    Xiuhua Weng*1, Shaohong Luo*1, Shen Lin*, Lixian Zhong, Meiyue Li*, Rao Xin*, Pinfang Huang*, Xiongwei Xu*

    Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132

    Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE- 042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental… More >

  • Open Access


    CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy

    Qie Guo*, Xiao Li*, Meng-Na Cui*, Jia-Lin Sun*, Hong-Yan Ji*, Bei-Bei Ni*, Mei-Xing Yan

    Oncology Research, Vol.28, No.5, pp. 533-540, 2020, DOI:10.3727/096504020X15919605976853

    Abstract Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence. More >

  • Open Access


    Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo

    Leonard Lothstein*, Judith Soberman, Deanna Parke*, Jatin Gandhi*, Trevor Sweatman, Tiffany Seagroves*

    Oncology Research, Vol.28, No.5, pp. 451-465, 2020, DOI:10.3727/096504020X15898794315356

    Abstract Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and… More >

  • Open Access


    PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients

    Andrea Lapucci*†1, Gabriele Perrone*†1, Antonello Di Paolo‡§, Cristina Napoli*†, Ida Landini*†, Giandomenico Roviello*†, Laura Calosi, Antonio Giuseppe Naccarato#, Alfredo Falcone#, Daniele Bani, Enrico Mini*†§2, Stefania Nobili*†§2,3

    Oncology Research, Vol.28, No.6, pp. 631-644, 2020, DOI:10.3727/096504020X16056983169118

    Abstract The benefit of adjuvant chemotherapy in the early stages of colorectal cancer (CRC) is still disappointing and the prediction of treatment outcome quite difficult. Recently, through a transcriptomic approach, we evidenced a role of PNN and KCNQ1OT1 gene expression in predicting response to fluoropyrimidine-based adjuvant chemotherapy in stage III CRC patients. Thus, the aim of this study was to validate in an independent cohort of stages II–III CRC patients our previous findings. PNN and KCNQ1OT1 mRNA expression levels were evaluated in 74 formalin-fixed paraffin-embedded tumor and matched normal mucosa samples obtained by stages II–III CRC patients treated… More >

Displaying 21-30 on page 3 of 38. Per Page